ABSTRACT
The current COVID-19 pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected the large population across the globe by serious respiratory illness and death. Since the medicine for this new disease is yet to discover, the treatment op-tions against pandemic COVID-19 are very limited and unsatisfactory. Further, the hospitals, wherethe COVID-19 patients are admitted for treatment, are the major source of the spread of this virus, as it survives on the surfaces of inanimate objects for days. Therefore, hospitals have become hotspots for SARS-CoV-2 infection. The non-availability of quality personal protective equipment (PPE) and exposure to severe COVID patients have been major factors for the infection in millions of healthcare workers. However, developing an effective medicine has remained challenging due to its unpredictable mutation rate. Here, this article describes functionalized photocatalytic nanocoat-ings to destroy the COVID-19 virus, which can be applied on the surface of inanimate objects, such as paper, cloth, glass, wood, ceramic, metallic, and polymeric surfaces. With the supporting experimental results, various possible ways of killing the virus and its relevant mechanism are dis-cussed. This article provides new insights for developing nano solutions to address this COVID-19 issue.Copyright © 2021 Bentham Science Publishers.
ABSTRACT
Combating the spread and deaths brought on by the new corona virus is a big challenge for the world today (COVID-19). The economic and medical costs of this infectious disease on the human population are enormous. Around the world, COVID-19 had a negative impact on education. There hasn't been a clear cure or vaccine recommended for COVID-19 as of yet. Different antiviral drug combinations are used by doctors. Additionally, plasma treatment is used. The only method to protect oneself is to keep a distance from others, practise good hygiene, and wear a mask. The use of nanotechnology can be particularly effective in the fight against COVID-19. Nanomedicine can make use of nanoparticles. For added protection, it can be coated or sprayed on a mask or PPE kit. It has also been used to identify Covid 19 patients early. Copyright © 2022 Wolters Kluwer Medknow Publications. All rights reserved.
ABSTRACT
Steroidal products have been found useful in inflammations associated with Covid 19. Prednisolone is one readily available steroid, which is often found as uncoated normal release tablets. Modified release prednisolone may be desirable in Covid 19 for sustained actions. This is expected to reduce dosing frequency and enhance compliance. This study is concerned with development of controlled release prednisolone using coating technology with bio-compatible, cross-linked starch-albumin films. Starches and proteins are excellent film formers with good flexibility, transparency, and bio-compatibility. The cross-linked starch-albumin films were prepared using glycerol as the plasticizer: starch (A), starch-albumin (B), starch-albumin cross-linked with formaldehyde at 1 % (C), 5 % (D) and 10 % (E). Equilibrium moisture sorption (EMS) at 100 % relative humidity, equilibrium swelling (ESC) in buffer solutions of pHs 2, 7 and 9, and DSC thermal properties were evaluated. In-vitro drug release from the film coated prednisolone tablets were evaluated in 0.1N HCl, water and phosphate buffer 8.0 as dissolution media. Films showed ESC in the order A>D>E>B>C;D>C>A>E>B and A>D>C>B>E in acidic, neutral and alkali media respectively. EMS was in the order B>E>A>D>C;with slight shift in the melting temperatures. In-vitro release at 240 min varied from 78 to 117 % (E>D>C>A>B);19 to 60 % (D>B>C>E>A) and 49 to 60 % (B>A>C>D>E) in 0.1N HCl, water and PBS respectively. Cross-linking improved the stability and swelling of films. The in-vitro release in alkaline medium suggests their usefulness for controlled drug delivery. New pH-responsive polymers, with improved physicochemical properties for coating prednisolone tablets were developed. Copyright © 2007, Nat. Inst. for Pharmaceutical Research and Development. All rights reserved.
ABSTRACT
The proceedings contain 226 papers. The topics discussed include: identification of biomarkers sensitive to pulsatile and continuous flow for identification of promising continuous flow VAD modulation protocols to mitigate non-surgical bleeding events;comprehensive machine learning analysis of pre-implantation risk factors for right heart failure after LVAD implantation;combining VA-ECMO And Impella (EC-Pella) before reperfusion mitigates left ventricular loading and injury due to VA-ECMO in acute myocardial infarction;platelet function at the intersection of the COVID-19 'cytokine storm' and mechanical circulatory support;a dialysate free portable artificial kidney device;durable right heart mechanical support system: a multi-day proof-of-concept study in pulmonary hypertension sheep;a dual-action nitric oxide-releasing slippery surface coating for extracorporeal organ support: first evaluation at clinically relevant blood flow rate for partial lung support;cannula add-on for pressure and flow measurement in VADs;and comparison of interlaboratory CFD simulations of the FDA benchmark blood pump model.
ABSTRACT
A mixed antigen coating method was designed to optimize the method for detecting the titer of the immune serum to inactivated SARS-CoV-2 vaccine, which based on the traditional single antigen coating.The authors determined the optimal coating concentration of the single antigen first by the checkerboard method, then combined two kinds of antigen and obtained coating concentration of the mixed antigen.The best combination of mixed coating antigen contains the whole-coronavirus antigen with total protein concentration of 25 ng/well and the recombinant new coro-navirus S1 protein antigen with protein concentration of 50 ng/well.This method can be used to detect all antibody-specific titers in serum effectively, especially serum containing high-level S protein-specific antibodies.
ABSTRACT
The proceedings contain 59 papers. The topics discussed include: transapical cannulation with a dual lumen cannula for mechanical circulatory support in cardiogenic shock;prolonged ECMO support of an adult with SARS-CoV-2 ARDS and right heart failure in a children's hospital;pushing geographical boundaries: interfacility transport and remote ECMO cannulation of patients during COVID pandemic;comparison of new viscoelastic coagulation monitor with standard of care thromboelastography for anticoagulation monitoring during 72-hour extracorporeal life support;comparison of NO metabolite levels during ex vivo extracorporeal circulation of blood using NO-eluting and NO-generating surface coatings;ex vivo evaluation of a nitric oxide catalyst surface coating for extracorporeal life support application;and practice variation in perceived optimal genetic testing across CHNC ECMO centers.